Valneva SE (VLA.PA)
| Chiusura precedente | 6,53 |
| Aperto | 6,50 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 6,36 - 6,54 |
| Intervallo di 52 settimane | 4,95 - 29,70 |
| Volume | |
| Media Volume | 427.549 |
| Capitalizzazione | 900,981M |
| Beta (5 anni mensile) | 1,30 |
| Rapporto PE (ttm) | 7,96 |
| EPS (ttm) | 0,81 |
| Prossima data utili | 10 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,19 |
- GlobeNewswire
Valneva Appoints Dipal Patel as Chief Commercial Officer
Saint-Herblain (France), November 17, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer (CCO) and Management Board member. With this newly created role, Valneva strengthens its management team with a recognized commercial industry leader as the Company advances its chikungunya vaccine candidate towards potential market entry in 2023. Ms. Patel is an established commercial leader with over
- GlobeNewswire
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
Total nine-month revenues of €249.9 million, a ~ 3.5-fold increase compared to 2021 Product sales of €74.4 million (vs €45.5 million in the first nine months of 2021) driven by a continued recovery of travel vaccine sales and by COVID-19 vaccine sales in Europe. Product sales outside of COVID-19 grew by double digits (11.2%) vs. prior period€175.5 million of other revenues (vs €24.4 million in the first nine months of 2021) mainly driven by revenue recognition related to previous COVID-19 vaccin
- GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Saint-Herblain (France), November 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference, to take place November 15-17, 2022 in London, England. Additionally, Mr. Lingelbach and Mr. Bühler will participate in a fireside chat on Tuesday,
